Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.

Not Applicable

Not yet recruiting

• Conditions: Allergy Pollen; Allergic Reaction; Allergic Skin Reaction
• Interventions: Other: Allergenic extract

• Registration Number: NCT05533385
• Lead Sponsor: Inmunotek S.L.

Brief Summary

The objective of this study is to determine the biological activity of Juniperus oxycedrus and Cupressus arizonica. allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

Detailed Description

The trial will consist of a single visit, in which the following procedures will be carried out:

* Demographic data.

* Clinical history.

* Inclusion/exclusion criteria.

* Physical examination.

* Pregnancy test.

* Performance of prick-tests (3 concentrations of Juniperus oxycedrus and Cupressus arizonica allergenic extract, positive control and negative control).

* Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract.

* Each serum sample will be stored in a tube labeled with the subject number and frozen. These serum samples will remain in the freezer until the end of the study. When the study is completed, they will be transported to the laboratory, where all sera will be pooled. This "pool" of sera will be used to perform the complementary in vitro tests necessary to standardize and characterize this extract and produce its corresponding IHRP (In-house reference preparation), as indicated by the Royal Spanish Pharmacopoeia and the European Pharmacopoeia. In addition, it will be used in the in vitro analyses necessary for the standardization of new batches of this allergenic extract. Once the pool has been formed, the tubes containing the original serum samples are destroyed.

* Evaluation of adverse events.

Study Timeline

• Status Verified: 2022-09
• Study First Submitted: 2022-09-05
• Study First Submitted QC: 2022-09-05
• Last Update Submitted: 2022-09-05
• Study First Posted: 2022-09-09
• Last Update Posted: 2022-09-09
• Study Start: 2023-01-02
• Primary Completion: 2024-01-31
• Study Completion: 2024-04-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Subjects must live in a geographical area where allergic problems caused by Juniperus oxycedrus and Cupressus arizonica are relevant.
• Positive clinical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to asthma) to Juniperus oxycedrus and Cupressus arizonica.
• A positive prick-test (mean papule diameter ≥ 3 mm) with an extract of the same allergen and/or presence of specific IgE against that allergen.
• The mean papule area obtained with Histamine dichlorhydrate at 10 mg/mL should be ≥ 7 mm2.
• Age: Between 18 and 64 years old.
• Both sexes.
• Subjects must be able to give informed consent.
• Women of childbearing age (since menarche) must present a negative urine pregnancy test at the time of enrollment in the trial.

Exclusion Criteria

• Subjects should not be excluded in terms of low or high sensitivity to Juniperus oxycedrus and Cupressus arizonica.
• Subjects outside the age range.
• Subjects who have previously received immunotherapy in the last 5 years for the treatment of asthma or rhinoconjunctivitis for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Juniperus oxycedrus and Cupressus arizonica extracts.
• Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in which the suspension of the systemic antihistamine treatment is contraindicated.
• Subjects who have previously presented a severe secondary reaction during the performance of diagnostic skin tests by prick test.
• Subjects under treatment with ß-blockers.
• Subjects clinically unstable (acute asthma, febrile, etc.).
• Subjects with active urticaria lesions, severe active dermographism, severe atopic dermatitis, sunburn, eczema, psoriasis lesions in the area where the prick test is performed (risk of false positives).
• Subjects with active viral infection by herpes simplex or herpes varicella zoster in the area where the prick test is performed.
• Subjects with any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HTA, cardiopathy, etc.).
• States of the subject in which he/she cannot offer cooperation and severe psychiatric disorders.
• Pregnant women or women at risk of pregnancy and lactating women.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Extract J. oxycedrus + extract C. arizonica + positive control + negative control	Allergenic extract	There is only one treatment arm. In each subject, one drop of each of the 3 concentrations of each allergenic extract (2 extracts) will be applied in addition to the positive control (histamine 10 mg/mL) and the negative control, with prick test. Juniperus oxycedrus: 300, 60 and 12 µg/mL Cupressus arizonica: 100, 20 and 4 µg/mL

Primary Outcome Measures

Name	Time	Method
Adverse reactions	30 minutes	Mild secondary reactions such as pruritus, erythema, local edema, etc. There is a risk, infrequent and exceptional, of systemic reactions, sometimes severe (urticaria, asthma, anaphylactic shock, etc.).
Size of the induced papule on the skin	15 minutes	Size of the induced papule on the skin when applying each of the concentrations of the allergenic extracts and the positive (histamine) and negative controls, using the prick test.

Trial Locations

Locations (1)

Clínica Subiza, centro de asma y alergia; 🇪🇸 Madrid, Spain